Does Clinical-CT ‘Mismatch’ Predict Early Response to Treatment with Recombinant Tissue Plasminogen Activator?

Publisher： Karger

E-ISSN： 1421-9786|22|5-6|384-388

ISSN： 1015-9770

Source： Cerebrovascular Diseases, Vol.22, Iss.5-6, 2006-11, pp. : 384-388

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Successful treatment of fulminant pneumococcal sepsis with recombinant tissue plasminogen activator

By Akol H.   Boon E.S.   van Haren F.M.P.   van der Hoeven J.G.  

European Journal of Internal Medicine, Vol. 13, Iss. 6, 2002-09 ,pp. : 389-391

Elsevier

Access to resources Recommend Favorite

Clinical and MRI Scale to Predict Very Poor Outcome in Tissue Plasminogen Activator Patients

By  

European Neurology, Vol. 65, Iss. 5, 2011-04 ,pp. : 291-295

Karger

Access to resources Recommend Favorite

Early Neurological Deterioration following Intravenous Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Lacunar Stroke

By  

Cerebrovascular Diseases, Vol. 26, Iss. 4, 2008-08 ,pp. : 355-359

Karger

Access to resources Recommend Favorite

Frequency and Predictors of Symptomatic Intracerebral Hemorrhage in Patients with Ischemic Stroke Treated with Recombinant Tissue Plasminogen Activator outside Clinical Trials

By  

Cerebrovascular Diseases, Vol. 23, Iss. 2-3, 2006-11 ,pp. : 85-90

Karger

Access to resources Recommend Favorite

Repeated Intravenous Treatment with Recombinant Tissue-Type Plasminogen Activator in Patients with Acute Ischemic Stroke

By  

European Neurology, Vol. 74, Iss. 3-4, 2015-09 ,pp. : 127-134

Karger

Access to resources Recommend Favorite